Biotech Values

[DewDiligence]

Sanofi Reports 1H09 Annualized Lovenox Sales of $4.3B

[The sales figures below are in Euros, Sanofi’s reporting currency, but the growth rates are in local currencies unless otherwise specified. Tallying growth in local currencies is a way to track the change in volume and price irrespective of exchange rates. The figures below are annualized, i.e. they are 2x the reported 1H09 numbers.]


Worldwide Lovenox sales in 1H09 rose 7% year-over-year in local currencies and 14% in Euros to an annualized rate of €3.08B, which is $4.3B at the current exchange rate.

In the US (where MNTA and NVS have filed an application to sell generic Lovenox), annualized 1H09 Lovenox sales were €1.87B, which is $2.6B at the current exchange rate.

The breakdown of 1H09 sales by geography is as follows (growth rates are year-over-year in local currencies):

US: €1.87B (61% of total), +2%
EU: €886M (29% of total), +13%
RoW: €324M (11% of total), +17%
===
Total: €3.08B, +7%

Source: http://en.sanofi-aventis.com/binaries/Half_year_financial_report_2009_Web_tcm28-25788.pdf